Nat Neurosci:华人学者千里挑一,找到脑瘤致命基因突变

2017-08-15 佚名 学术经纬

来自耶鲁大学(Yale University)系统生物学研究所的Sidi Chen教授团队与瑞士的Randall Platt教授课题组合作,用CRISPR技术,成功找到了导致胶质母细胞瘤的关键基因突变。这项研究发表在了《自然》子刊《Nature Neuroscience》上

随着CRISPR基因编辑技术的不断成熟,越来越多奋斗在前沿的科学家们开始探索它的无限应用潜力。


▲本项研究的负责人之一Sidi Chen教授(图片来源:耶鲁大学)

来自耶鲁大学(Yale University)系统生物学研究所的Sidi Chen教授团队与瑞士的Randall Platt教授课题组合作,用CRISPR技术,成功找到了导致胶质母细胞瘤的关键基因突变。这项研究发表在了《自然》子刊《Nature Neuroscience》上。

胶质母细胞瘤是一种恶性脑肿瘤,极难治疗。据估计,在确诊后,约一半的患者只能活上1-1.5年。不幸的是,我们非但没有治疗这种疾病的好方法,甚至连它背后的原因都没有摸清。目前,生物学家们知道有超过223条基因和这个疾病有关。但我们不知道哪几条基因,或者是哪些基因的组合会导致这些癌症。这也是Chen教授团队的研究重点。

在耶鲁大学,Chen教授的研究重点在于开发新型工具,并将它们应用于下一代的癌症遗传学、基因组学、以及系统生物学。这些工具有助于解决癌症病发、进展、转移等一系列问题,并可以为潜在的治疗方案提供洞见。


▲该研究的筛选手段(图片来源:《Nature Neuroscience》)

为了寻找到会导致胶质母细胞瘤的基因突变,Chen教授团队利用CRISPR基因编辑技术,开发了一种全新的筛选手段。首先,他们在数据库中找到了人类脑癌中常见的基因突变,并由此构建了一套sgRNA库,用于CRISPR编辑。随后,他们使用了腺相关病毒(AAV)技术,将这些能突变特定基因的系统引入到了小鼠脑内。之后,他们观察这些小鼠是否会出现胶质母细胞瘤的症状。由这些发病的小鼠,研究人员能反推出哪些基因突变会诱发这种致命脑瘤。

如他们所料,不少小鼠都出现了胶质母细胞瘤。对于这些大脑组织的后续测序分析,研究人员们发现一些基因突变特别常见。Pten、Nf1、B2m、Trp53等参与到细胞周期、免疫调控、以及DNA修复与复制的基因,突变的频率更是要超过70%。这些结果表明了这些基因在胶质母细胞瘤的病发中或许起到了关键作用。


▲一些基因突变在组织样本中很常见(图片来源:《Nature Neuroscience》)

由于CRISPR技术的高效和精准,研究人员能够一次让多条基因产生突变。这也让他们得以分析不同的基因突变组合在胶质母细胞瘤里的影响。在分析中,研究人员一共评估了超过1500种突变组合。其中,B2m–Nf1、Mll3–Nf1、以及Zc3h13–Rb1这些基因组合被认为是诱发脑瘤的主要共同驱动因素。

除了找到潜在的致癌因素外,这项研究还为治疗提供了洞见。研究人员想要知道,这些基因突变是否会影响脑瘤的治疗。因此,他们为不同的突变小鼠进行了替莫唑胺(temozolomide)化疗,观察这些小鼠的治疗成效。实验发现,带有Zc3h13或Pten突变的小鼠,对化疗的反应尤其差。这或许能为胶质母细胞瘤的治疗提供新思路——如果患者体内带有这些突变,医生就应当考虑化疗外的治疗方案。


▲胶质母细胞瘤这种顽疾,有望迎来个体化的治疗方案(图片来源:维基百科)

“我们已经对人类癌症基因组进行了测序,有数千个新基因突变和癌症联系到了一起。但是之前还很难证明哪些基因,或者哪些基因组合真正导致了癌症,”Chen教授说:“如今,我们能利用这些信息,来决定哪些药物最有可能对单独的患者带来好的疗效。这离个体化癌症治疗又近了一步。”

我们祝贺Chen教授课题组的成果顺利发表,也祝愿他们的工具能帮助找到更多治疗癌症的新靶点,为患者带来更好的治疗方案。

原始出处:Ryan D Chow, Christopher D Guzman, Guangchuan Wang, et al. AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma. Nat Neurosci (2017)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1882369, encodeId=37c118823699c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jan 12 16:59:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810865, encodeId=8e89181086585, content=<a href='/topic/show?id=95d58640830' target=_blank style='color:#2F92EE;'>#致命基因突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86408, encryptionId=95d58640830, topicName=致命基因突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Mon Feb 05 13:59:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275691, encodeId=a59b12e5691eb, content=<a href='/topic/show?id=aad38494640' target=_blank style='color:#2F92EE;'>#脑瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84946, encryptionId=aad38494640, topicName=脑瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Thu Aug 17 01:59:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364221, encodeId=05ca1364221f3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Aug 17 01:59:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581967, encodeId=0aee158196e53, content=<a href='/topic/show?id=830c35868ec' target=_blank style='color:#2F92EE;'>#华人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35868, encryptionId=830c35868ec, topicName=华人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f7716881423, createdName=ms4468361851264128, createdTime=Thu Aug 17 01:59:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623001, encodeId=3be9162300154, content=<a href='/topic/show?id=54a7358e4cb' target=_blank style='color:#2F92EE;'>#华人学者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35874, encryptionId=54a7358e4cb, topicName=华人学者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1720449156, createdName=zhangxingru, createdTime=Thu Aug 17 01:59:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233804, encodeId=0ccf23380476, content=非常好的文章,学习了,很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Tue Aug 15 12:11:04 CST 2017, time=2017-08-15, status=1, ipAttribution=)]
    2018-01-12 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1882369, encodeId=37c118823699c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jan 12 16:59:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810865, encodeId=8e89181086585, content=<a href='/topic/show?id=95d58640830' target=_blank style='color:#2F92EE;'>#致命基因突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86408, encryptionId=95d58640830, topicName=致命基因突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Mon Feb 05 13:59:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275691, encodeId=a59b12e5691eb, content=<a href='/topic/show?id=aad38494640' target=_blank style='color:#2F92EE;'>#脑瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84946, encryptionId=aad38494640, topicName=脑瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Thu Aug 17 01:59:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364221, encodeId=05ca1364221f3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Aug 17 01:59:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581967, encodeId=0aee158196e53, content=<a href='/topic/show?id=830c35868ec' target=_blank style='color:#2F92EE;'>#华人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35868, encryptionId=830c35868ec, topicName=华人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f7716881423, createdName=ms4468361851264128, createdTime=Thu Aug 17 01:59:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623001, encodeId=3be9162300154, content=<a href='/topic/show?id=54a7358e4cb' target=_blank style='color:#2F92EE;'>#华人学者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35874, encryptionId=54a7358e4cb, topicName=华人学者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1720449156, createdName=zhangxingru, createdTime=Thu Aug 17 01:59:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233804, encodeId=0ccf23380476, content=非常好的文章,学习了,很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Tue Aug 15 12:11:04 CST 2017, time=2017-08-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1882369, encodeId=37c118823699c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jan 12 16:59:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810865, encodeId=8e89181086585, content=<a href='/topic/show?id=95d58640830' target=_blank style='color:#2F92EE;'>#致命基因突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86408, encryptionId=95d58640830, topicName=致命基因突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Mon Feb 05 13:59:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275691, encodeId=a59b12e5691eb, content=<a href='/topic/show?id=aad38494640' target=_blank style='color:#2F92EE;'>#脑瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84946, encryptionId=aad38494640, topicName=脑瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Thu Aug 17 01:59:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364221, encodeId=05ca1364221f3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Aug 17 01:59:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581967, encodeId=0aee158196e53, content=<a href='/topic/show?id=830c35868ec' target=_blank style='color:#2F92EE;'>#华人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35868, encryptionId=830c35868ec, topicName=华人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f7716881423, createdName=ms4468361851264128, createdTime=Thu Aug 17 01:59:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623001, encodeId=3be9162300154, content=<a href='/topic/show?id=54a7358e4cb' target=_blank style='color:#2F92EE;'>#华人学者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35874, encryptionId=54a7358e4cb, topicName=华人学者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1720449156, createdName=zhangxingru, createdTime=Thu Aug 17 01:59:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233804, encodeId=0ccf23380476, content=非常好的文章,学习了,很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Tue Aug 15 12:11:04 CST 2017, time=2017-08-15, status=1, ipAttribution=)]
    2017-08-17 jxrzshh
  4. [GetPortalCommentsPageByObjectIdResponse(id=1882369, encodeId=37c118823699c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jan 12 16:59:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810865, encodeId=8e89181086585, content=<a href='/topic/show?id=95d58640830' target=_blank style='color:#2F92EE;'>#致命基因突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86408, encryptionId=95d58640830, topicName=致命基因突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Mon Feb 05 13:59:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275691, encodeId=a59b12e5691eb, content=<a href='/topic/show?id=aad38494640' target=_blank style='color:#2F92EE;'>#脑瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84946, encryptionId=aad38494640, topicName=脑瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Thu Aug 17 01:59:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364221, encodeId=05ca1364221f3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Aug 17 01:59:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581967, encodeId=0aee158196e53, content=<a href='/topic/show?id=830c35868ec' target=_blank style='color:#2F92EE;'>#华人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35868, encryptionId=830c35868ec, topicName=华人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f7716881423, createdName=ms4468361851264128, createdTime=Thu Aug 17 01:59:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623001, encodeId=3be9162300154, content=<a href='/topic/show?id=54a7358e4cb' target=_blank style='color:#2F92EE;'>#华人学者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35874, encryptionId=54a7358e4cb, topicName=华人学者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1720449156, createdName=zhangxingru, createdTime=Thu Aug 17 01:59:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233804, encodeId=0ccf23380476, content=非常好的文章,学习了,很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Tue Aug 15 12:11:04 CST 2017, time=2017-08-15, status=1, ipAttribution=)]
    2017-08-17 lsndxfj
  5. [GetPortalCommentsPageByObjectIdResponse(id=1882369, encodeId=37c118823699c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jan 12 16:59:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810865, encodeId=8e89181086585, content=<a href='/topic/show?id=95d58640830' target=_blank style='color:#2F92EE;'>#致命基因突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86408, encryptionId=95d58640830, topicName=致命基因突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Mon Feb 05 13:59:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275691, encodeId=a59b12e5691eb, content=<a href='/topic/show?id=aad38494640' target=_blank style='color:#2F92EE;'>#脑瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84946, encryptionId=aad38494640, topicName=脑瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Thu Aug 17 01:59:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364221, encodeId=05ca1364221f3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Aug 17 01:59:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581967, encodeId=0aee158196e53, content=<a href='/topic/show?id=830c35868ec' target=_blank style='color:#2F92EE;'>#华人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35868, encryptionId=830c35868ec, topicName=华人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f7716881423, createdName=ms4468361851264128, createdTime=Thu Aug 17 01:59:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623001, encodeId=3be9162300154, content=<a href='/topic/show?id=54a7358e4cb' target=_blank style='color:#2F92EE;'>#华人学者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35874, encryptionId=54a7358e4cb, topicName=华人学者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1720449156, createdName=zhangxingru, createdTime=Thu Aug 17 01:59:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233804, encodeId=0ccf23380476, content=非常好的文章,学习了,很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Tue Aug 15 12:11:04 CST 2017, time=2017-08-15, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1882369, encodeId=37c118823699c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jan 12 16:59:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810865, encodeId=8e89181086585, content=<a href='/topic/show?id=95d58640830' target=_blank style='color:#2F92EE;'>#致命基因突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86408, encryptionId=95d58640830, topicName=致命基因突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Mon Feb 05 13:59:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275691, encodeId=a59b12e5691eb, content=<a href='/topic/show?id=aad38494640' target=_blank style='color:#2F92EE;'>#脑瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84946, encryptionId=aad38494640, topicName=脑瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Thu Aug 17 01:59:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364221, encodeId=05ca1364221f3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Aug 17 01:59:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581967, encodeId=0aee158196e53, content=<a href='/topic/show?id=830c35868ec' target=_blank style='color:#2F92EE;'>#华人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35868, encryptionId=830c35868ec, topicName=华人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f7716881423, createdName=ms4468361851264128, createdTime=Thu Aug 17 01:59:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623001, encodeId=3be9162300154, content=<a href='/topic/show?id=54a7358e4cb' target=_blank style='color:#2F92EE;'>#华人学者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35874, encryptionId=54a7358e4cb, topicName=华人学者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1720449156, createdName=zhangxingru, createdTime=Thu Aug 17 01:59:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233804, encodeId=0ccf23380476, content=非常好的文章,学习了,很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Tue Aug 15 12:11:04 CST 2017, time=2017-08-15, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1882369, encodeId=37c118823699c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jan 12 16:59:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810865, encodeId=8e89181086585, content=<a href='/topic/show?id=95d58640830' target=_blank style='color:#2F92EE;'>#致命基因突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86408, encryptionId=95d58640830, topicName=致命基因突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Mon Feb 05 13:59:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275691, encodeId=a59b12e5691eb, content=<a href='/topic/show?id=aad38494640' target=_blank style='color:#2F92EE;'>#脑瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84946, encryptionId=aad38494640, topicName=脑瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Thu Aug 17 01:59:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364221, encodeId=05ca1364221f3, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Aug 17 01:59:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581967, encodeId=0aee158196e53, content=<a href='/topic/show?id=830c35868ec' target=_blank style='color:#2F92EE;'>#华人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35868, encryptionId=830c35868ec, topicName=华人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f7716881423, createdName=ms4468361851264128, createdTime=Thu Aug 17 01:59:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623001, encodeId=3be9162300154, content=<a href='/topic/show?id=54a7358e4cb' target=_blank style='color:#2F92EE;'>#华人学者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35874, encryptionId=54a7358e4cb, topicName=华人学者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1720449156, createdName=zhangxingru, createdTime=Thu Aug 17 01:59:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233804, encodeId=0ccf23380476, content=非常好的文章,学习了,很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Tue Aug 15 12:11:04 CST 2017, time=2017-08-15, status=1, ipAttribution=)]
    2017-08-15 天涯183

    非常好的文章,学习了,很受益

    0

相关资讯

Nature:生存时间延长67%!科学家瞄准肿瘤微环境,找到治疗胶质母细胞瘤的关键基因!

终于,在克利夫兰诊所Jeremy Rich教授团队的不懈努力下,一种体内筛选抗肿瘤药物靶点的新方法诞生了! Rich教授是胶质母细胞瘤领域的专家,可是对于这种侵袭性极强,中位生存期只有15个月,5年生存率在6%左右,被称为「癌症之王」的癌症,他也束手无策。 在Rich教授看来,这可能是研究的方法出了问题。 「传统药物研发是从体外培养癌细胞开始的,然后做高通量筛选。」Rich教授在论文中表

N Engl J Med:短期放射加替莫唑胺治疗老年患者胶质母细胞瘤

胶质母细胞瘤与老年人的予后不良相关。当将替莫唑胺化疗加入标准放疗(60 Gy,6周)时,70岁以上患者的生存率显着增加。在老年患者中,通常使用更方便的较短的放射疗法,但是在较短的放疗过程中添加替莫唑胺的好处仍还是未知的。

CLIN CANCER RES:GRP78抗体增强胶质母细胞瘤及非小细胞肺癌放疗疗效

非小细胞肺癌及胶质母细胞瘤预后差。两种肿瘤高表达GRP78,GRP78在放疗抵抗及肿瘤复发方面起到一定作用。CLIN CANCER RES近期发表了一篇文章,研究抗GRP78抗体以及抗GRP78抗体联合放疗对非小细胞肺癌及胶质母细胞瘤的影响。

Neurology:新确诊胶质母细胞瘤患者延长TMZ化疗效果如何?

2017年4月,发表在《Neurology》的一项由德国科学家进行的研究考察了对新确诊胶质母细胞瘤的患者,替莫唑胺延长治疗时间的疗效。 目的:在新确诊胶质母细胞瘤患者中,考察改良目前治疗标准——手术后进行放疗+同步6个周期替莫唑胺维持化疗(TMZ/RT→TMZ)中,将TMZ扩展至6个周期以上与生存期的相关性。 方法:从德国Glioma Network队列中,筛选出使用TMZ/RT→TMZ,且完

NEJM:荧光素导向在胶质母细胞瘤切除术中的应用-案例报道

该患者术后四周,开始接受放疗和替莫唑胺治疗。术后2个月随访,该患者无头痛症状,以及无神经功能缺损。

Sci Transl Med:重磅疗法治疗脑瘤,研究展现曙光

在一项临床试验中,研究人员们招募了一批表达EGFRvIII,且病情出现复发的胶质母细胞瘤患者。利用这些患者体内的T细胞,研究人员开发出了CAR-T-EGFRvIII疗法,特异性地针对患者的癌细胞。